financetom
Business
financetom
/
Business
/
India's SpiceJet says Carlyle Aviation will write off $40 mln of lease arrears
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's SpiceJet says Carlyle Aviation will write off $40 mln of lease arrears
Sep 11, 2024 12:18 AM

BENGALURU, Sept 10 (Reuters) - India's SpiceJet

said on Tuesday that Carlyle Group's ( CG ) commercial

aviation investment and servicing unit will write off $40.2

million of the airline's lease arrears and convert $30 million

of its arrears into equity.

The conversion, at 100 rupees ($1.19) per share of Spicejet,

is a 56% premium to its close on Monday.

The budget carrier's shares jumped as much as 6% after the

announcement.

The conversion will "significantly increase" Carlyle

Aviation's stake in the carrier, Spicejet said.

It was not immediately clear how much stake Carlyle Aviation

held in SpiceJet.

($1 = 83.9700 Indian rupees)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Butler National Insider Bought Shares Worth $268,607, According to a Recent SEC Filing
Butler National Insider Bought Shares Worth $268,607, According to a Recent SEC Filing
Jan 6, 2025
04:39 PM EST, 01/06/2025 (MT Newswires) -- Joseph Patrick Daly, 10% Owner, Director, on January 03, 2025, executed a purchase for 157,800 shares in Butler National ( BUKS ) for $268,607. Following the Form 4 filing with the SEC, Daly has control over a total of 8,358,000 shares of the company, with 4,110,000 shares held directly and 4,248,000 controlled indirectly....
AbbVie cuts 2024 profit forecast on acquisition expenses
AbbVie cuts 2024 profit forecast on acquisition expenses
Jan 6, 2025
Jan 6 (Reuters) - AbbVie ( ABBV ) lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs. The company has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection last year. To that end, AbbVie ( ABBV...
Denali Therapeutics ALS drug fails in mid-stage trial
Denali Therapeutics ALS drug fails in mid-stage trial
Jan 6, 2025
Jan 6 (Reuters) - Denali Therapeutics ( DNLI ) said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. ...
Roadzen Closes $5 Million Public Offering
Roadzen Closes $5 Million Public Offering
Jan 6, 2025
04:40 PM EST, 01/06/2025 (MT Newswires) -- Roadzen ( RDZN ) closed its public offering of 2.22 million ordinary shares at $2.25 apiece for gross proceeds of $5 million. Net proceeds will be mainly for costs related to sales and marketing, for research and development, working capital and general corporate purposes, the company said Monday in a statement. Roadzen (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved